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Summary We attempted to induce anti-tumour immunity for rejecting pre-B lymphoma derived from Eu/ret
transgenic mice (TGM). We established pre-B-lymphoma cell lines of C57BL/6 x Balb/c background (H-2bI/d)
into which H-2k alloantigen and C3H background were introduced (retLl-6 and retL6-6), and we inoculated
BCF, mice with these immunising tumour cells. After these tumours were rejected by alloantigen (H-2k/C3H
background)-specific effector cells, the mice were challenged with the pre-B-lymphoma cell line derived from
the original EJL/ret TGM (retO-2). All non-immunised control mice died within 80 days, whereas half the
immunised mice survived for over 300 days. The immunity was also effective against primary pre-B-lymphoma
cells from Eli/ret TGM and the ret-driven melanoma cell line (MEL-ret), but not against the pre-B-lymphoma
cell line from Ejlmyc TGM. This immunity was at least in part mediated by cell-mediated cytotoxicity that
was specific to the ret oncogene product or ret-regulated antigen. Next we immunised Ep/ret TGM by
inoculating them with retL6-6 cells once every 2 weeks beginning at the age of 1 month. Interestingly, this
immunisation enabled the TGM to survive longer than the non-immunised control group (P<0.05).
Moreover, 2 of 11 transgenic mice receiving such immunisation were free from both macroscopic and
microscopic tumours at the time when all of the 12 non-immunised control TGM had died from their tumour.
This provides a new model for oncogene-linked immunotherapy research.
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Different types of tumour antigens have been found on
malignant tumours in humans and laboratory animals (Klein,
1966; Old and Stockert, 1977; Schreiber et al., 1988; Urban
and Schreiber, 1992). Many of them are simply recognised by
antibodies and helper T cells, and only some of them act in
rejecting tumours. The former type of antigens are useful for
the diagnosis of tumours and for targeting tumours with
toxic reagents, but only the latter are active in the
immunological surveillance of tumours and can be best used
for therapeutic and prophylactic purposes. Well-known
tumour rejection antigens are nuclear antigens of tumour
viruses such as SV40 T antigen (Klein, 1966), adenovirus
ElA antigen (Dyson et al., 1992) and papillomavirus type 16
nucleoprotein (Chen et al., 1988), proteolysed fragments
(peptides) of which can associate with class I major his-
tocompatibility complex (MHC) antigens to be recognised by
cytotoxic T lymphocytes (CTL). So-called unique antigens of
chemically induced tumours and ultraviolet-induced tumours
(Schreiber et al., 1988) also play a role in tumour rejection.
Some of them have been characterised as the 85 kDa (Ulrich
et al., 1986) and 96 kDa (Srivastava et al., 1986) stress-
induced proteins or unique class I MHC antigens (Linsk et
al., 1986; Stauss et al., 1986) or P9lA (Lurquin et al., 1989)
and P198 (Sibille et al., 1990) with mutations of a single
nucleotide. Little is known, however, about the potential
tumour rejection antigens occurring on spontaneously arising
tumours in humans and laboratory animals, although the
antigen recognised by autologous CTL on human melanomas
has been recently shown to be encoded by the tyrosinase gene
(Brichard et al., 1993), and a human homologue of the
murine rejection antigen gp96 has been reported (Maki et al.,
1990).
Recent progress in oncology has revealed the multistep
actions of oncogenes in oncogenesis (Cory and Adams,
1988). The products of these oncogenes may be antigenic
because of the occurrence of point mutations, deletion muta-
tions or chromosomal translocation (Hellstrom and Hell-
strom, 1989; Urban and Schreiber, 1992). There are many
reported examples of tumour-specific antigens closely linked
to oncogene proteins, such as mutated ras p21 (Feramisco et
al., 1985; Pullano et al., 1989; Jung and Schluesener, 1991;
Peace et al., 1991), the bcl-abl fusion protein (Van Denderen
et al., 1989), mutated p53 (Gannon et al., 1990) adid the
deletion mutants of epidermal growth factor receptor (Hum-
phrey et al., 1990). These tumour antigens are, in most cases,
recognised by antibodies and helper T cells for antibody
production. Exceptions are mutated p53, which is a nuclear
suppressor gene product (Yanuck et al., 1993), and mutated
ras proteins produced by recombinant vaccina viruses (Skip-
per and Stauss, 1993), which are recognised by CTL. So far,
it is not known whether non-nuclear oncogene proteins in
native tumour cells will act as tumour rejection antigens and
whether only restricted mutational changes of the proteins
can induce tumour rejection immunity.
We recently established Eli/ret (Iwamoto et al., 1991a) and
MT/ret (Iwamoto et al., 1991b) transgenic mice (TGM), in
which pre-B lymphoma and melanocytic tumours developed
respectively. The ret oncogene, introduced into the TGM, is
a fusion gene of the protein tyrosine kinase proto-ret, whose
sequence coding the receptor domain is replaced with another
gene named rfp (Takahashi et al., 1985), and the Ret protein
is expressed in association with cell membrane (Taniguchi et
al., 1992). In order to determine the answers to the two
questions posed above, we tried to induce rejection immunity
against these tumours. A new method was used to modify the
transgenic tumour for immunisation; modified tumour cell
lines were established from the tumour arising in the trans-
genic mice into which alloantigens were introduced by cross-
ing. The results show that the ret oncogene is active in
inducing anti-tumour immunity which is effective in rejecting
both transgenic tumours transplanted into otherwise
genetically compatible hosts and tumours arising in trans-
genic mice in situ.
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Materials and methods
Mice
C57BL/6 x Balb/c F1 (BCF1) (H-2b/d) and Balb/c females
were bred in the Institute for Animal Research, Nagoya
University School of Medicine, or purchased from Shizuoka
Agricultural Center, Hamamatsu, Shizuoka. The En/ret
TGM were previously established from BCF1 mice (Iwamoto
et al., 1991a). E.lret TGM were bred with Balb/c, and the
progeny containing the transgene were selected as previously
described (Iwamoto et al., 1991a).
Cells
retO-2 was established from lymphoma developed in an EI./
ret TGM. MEL-ret (Taniguchi et al., 1992), a melanoma cell
line, was derived from a metallothionein/ret TGM (Iwamoto
et al., 1991b). An EiL/myc pre-B-lymphoma cell line of
C57BL/6 background (Yukawa et al., 1989) was kindly
donated by Dr Yukawa (Institute for Molecular and Cellular
Biology, Osaka University). These cell lines, which are listed
in Table I together with their H-2 haplotypes, were used as
challenging tumours to the previously immunised BCF, mice.
Establishment ofimmunising tumour cell lines
In our previous study, we induced a strong anti-tumour
immunity to original tumour cells by immunisation with the
tumour cells xenogenised by introducing allogeneic MHC
Class I gene (Isobe et al., 1989). Instead of transfecting with
the allogeneic MHC class I gene, we bred the Eu/ret TGM
with C3H/HeJ mice expressing H-2k antigen to obtain lym-
phoma cell lines possessing the same character as retO-2
except for the H-2k/C3H background expression. We estab-
lished two lymphoma cell lines (H-2d/k), retLl-6 and retL6-6,
as immunising tumour cells (Table I).
Immunisation procedure
BCF, male mice (2-3 months old) received i.p. injections of
1 x i07 immunising tumour cells twice in a month. Two
weeks after the last i.p. injection, challenging tumour cells
were injected i.p. into the mice and the survival time was
estimated as compared with that of control mice that did not
receive immunising tumour cells.
We also evaluated the effects of immunisation on tumour
development in Ep/ret TGM. A group of E!L/ret TGM
received repeated i.p. injections of 1 x 107 immunising
tumour cells once every 2 weeks from the age of 1 month.
Survival times from their birth were compared with those of
control TGM that did not receive immunising tumour cells.
Some mice were sacrificed and examined pathologically.
Assayfor cell-mediated cytotoxicity
Spleen cells suspended in RPMI-1640 medium containing
10% fetal calf serum were sensitised in vitro with tumour
cells irradiated with 1500 rad at a stimulator-to-target ratio
of 1:10 for 4 days. The cytotoxicity of these cells was
measured by the 51Cr-release assay. Target cells were labelled
Table I A list of transgenic tumour cell lines used in this study
Transgenic
Cell line oncogene H-2 Usedfor
retO-2 ret b/d Challenge in vivo
Target of in vitro killing
retLl-6 ret k/d Immunisation
retL6-6 ret k/d Immunisation
Target of in vitro killing
MEL-ret ret b Challenge in vivo
Target of in vitro killing
Eu/myc pre-B myc b Challenge in vivo
Target of in vitro killing
with 5"Cr, mixed with effector cells and incubated for 4 h at
37°C. The supernatant was collected for measurement of
radioactivity by a gamma scintillation counter. The percen-
tage of specific lysis was calculated as follows:
Specific lysis (%) = (experimental c.p.m. -
spontaneous c.p.m.)/(maximum c.p.m. -
spontaneous c.p.m.) x 100
Statistical analysis
The survival rate was calculated using the Kaplan-Meier
method. Statistical analysis was based on generalised Wil-
coxon tests. Values were expressed as the mean ± standard
deviation (s.d.).
Results
Characterisation ofthe immunising/challenging tumour cell
lines
We first examined the characteristics of the immunising/
challenging tumour cell lines. The negative cell-surface Ig
expression and the selective rearrangement of the immuno-
globulin heavy-chain genes indicated that the cell lines retO-2,
retLl-6 and retL6-6 had the pre-B-lymphoma phenotype. A
difference in the rearranged band size of the immunoglobulin
gene between retLl-6 and retL6-6 showed that these lym-
phoma cell lines were different clones (data not shown). As
might be anticipated, these two cell lines, which expressed
H-2k antigen, were completely rejected in BCF1 mice after i.p.
inoculation (data not shown).
Induction ofanti-tumour immunity rejecting ret TGM-derived
tumour cells
Figure 1 shows the survival time of mice previously
immunised with retLl-6 or retL6-6 after challenging with
2 x 106 retO-2 cells. Both retLl-6 and retL6-6 cell lines
induced anti-tumour immunity, rejecting retO-2 cells. One-
half to two-thirds of the mice survived more than 300 days
after challenge. On the other hand, all the mice that had not
been immunised died within 100 days. This difference was
statistically significant (P<0.01). These data demonstrated
that two different lymphoma cell lines (retLl-6, retL6-6)
independently induced anti-tumour immunity to the other
lymphoma cell line (retO-2). When we inoculated 1 x 107 of
retLO-2 cells into the immunised mice, however, there was no
statistically significant difference in the survival time between
immunised and non-immunised mice, although the survival
time of immunised mice was slightly longer than that of the
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Figure 1 Induction of anti-tumour immunity rejecting TGM-
derived tumour cells in BCF1 mice. RetLl-6 and retL6-6 cells at
(1 x 101) were injected intraperitoneally (i.p.) into BCF1 mice
twice in a month. Two weeks after the last injection, retO-2 cells
wene challenged at 2 x 106 i.p. into these mice and into non-
immunised control mice. Survival rate was recorded in days post
tumour challenge.
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non-immunised mice (data not shown). This result showed
that the immunity induced was not very strong.
Next, we evaluated the specificity of the anti-tumour
immunity induced by retL6-6 (Figure 2). Even when
challenged by primary lymphoma cells from Ell4ret TGM,
immunised mice survived longer (P<0.05) than non-
immunised mice. Interestingly, the anti-tumour immunity
induced by immunisation with Elt/ret B-lymphoma cells was
also directed against MEL-ret melanoma cells, while no
significant effect was observed on Efl4myc TGM-derived pre-
B-lymphoma cells. These data suggested that the induced
anti-tumour immunity was specific to the ret oncogene pro-
duct or its closely related antigen.
A further study was conducted to determine whether cell-
mediated cytotoxicity was induced by the immunising pro-
tocol. After inoculation of retL6-6 cells and retO-2 cells into
mice and in vitro secondary sensitisation of spleen cells from
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these mice with retO-2 cells, the effector activity developed to
kill retO-2 cells in addition to retL6-6 cells. The effector cells
also killed MEL-ret cells, but not Elt/myc TGM-derived
pre-B-lymphoma cells (Table II). These results confirmed the
specificity of the induced immunity against ret TGM-derived
tumours.
Suppression of tumour development in Els-ret TGM by
immunisation
As the final goal of this immunisation, we tested whether this
immunisation procedure could suppress tumour development
in EiL/ret TGM in situ. Figure 3 shows the survival time of
the TGM which had or had not been immunised with retL6-
6 cells. This immunisation enabled the TGM to survive
longer than the non-immunised control group (P<0.05).
Autopsies were performed on all mice tested. In the non-
immunised control group, all 12 TGM died from progression
of lymphoma by day 174 after birth. In the immunised
group, however, 8 of 11 (73%) TGM survived until day 174,
three of which showed no evidence of lymphoma develop-
ment on superficial examination. Two of these TGM were
sacrificed, and another died of severe general emaciation, for
reasons unknown. Pathological examination revealed that
one of them had a lymphomatous mass in the abdomen, but
the other two were pathologically free of lymphoma develop-
ment (Figure 4a-c). This contrasted with extensive prolifera-
tion of lymphoma cells observed in the lymph nodes (Figure
4d and e) and bone marrow (Figure 4f) of all mice in the
control group. Transmission of the ret gene into those
lymphoma-free mice was confirmed by repeated testing from
tail DNA.
Discussion
This study shows that pre-B-lymphoma cells arising in the
EfL/ret transgenic mouse carry tumour antigens which induce
anti-tumour immunity for both in vivo tumour rejection and
in vitro tumour cell killing. This immunity was not as strong
as that produced by virally or chemically induced tumours.
However, the immunity was effective not only in prolonging
the survival ofmice transplanted with the tumour, but also in
suppressing the primary development of the tumour in the
TGM in situ (Figure 3). The latter finding is particularly
notable because it for the first time provides evidence that
cellular oncogene-induced tumours may be subject to
oncogene product-linked immunological surveillance.
Analysis using four different types of ret-transgenic tumour
cells as the target of the immunity, all of which except the
transgenic ret were genetically compatible with the host
immune system, demonstrated that the immunity was ret-
specific or ret-linked. Three types of ret transgenic tumour
Figure 2 Specificity of the induced anti-tumour immunity. After
immunisation with retL6-6 according to the same procedure des-
cribed in Figure 1, primary tumour cells from E4/ret TGM
(H-2b) at 5 x 106 (a), MEL-ret, melanocyte tumour cell line at
4 x 106 (b) and Eu/myc TGM-derived pre-B-lymphoma cells at
2 x 104 (c) were injected i.p. into the immunised and unim-
munised control BCF, mice. Survival rate was recorded in days
post tumour challenge.
Table II Specificity of the in vitro cytotoxicity induced by the
immunisation with retL-6-6
51CR release (%) against
EIT ratio retO-2 MEL-ret Eit/myc pre-B retL6-6
50 28.2 + 2.0 25.6 + 2.2 0 + 0 52.3 + 2.5
10 16.5 + 1.9 15.8 + 1.7 0 + 0 12.7 + 1.6
1 1.9+2.7 4.1 +0.7 0+0 0.1 +0
RetL6-6 immunised mice were inoculated twice with 2 x 106 retO-2
cells. The spleen cells obtained from these mice I week after the last
injection of retO-2 were sensitised in vitro with ret0-2 and assayed for
the lytic activity against the target cells.
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Figure 3 Suppression of tumour development in Et/ret TGM by
immunisation. Ep/ret TGM received repeated i.p. injections of
immunising 1 x 107 retL6-6 cells once every 2 weeks from the age
of I month. Survival times from their birth were evaluated as
compared with those ofcontrol E4/ret TGM that did not receive
immunising tumour cells. Two mice from the immunising group
(*) which were free of lymphoma development on superficial
observation were sacrificed and examined pathologically. Triang-
les in this figure indicate the times when retL6-6 cells were
injected into TGM.
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Figure 4 Complete suppression of tumour development in some TGM of the immunised group. The histology of the lymph node and bone marrow from one of the two TGM sacrificed on day 174 (see Figure 3) and a control non-immunised TGM that died on that day is shown. Note that there is no evidence oflymphoma development in the normal structure of the peripheral lymph node with primary and secondary follicles (d and e) and bone marrow (f) from the immunised TGM, which contrasted with extensive
proliferation of lymphoma cells in the peripheral lymph node (a and b) and bone marrow (c) from the non-immunised control
TGM, destroying the normal structure. Stained with haematoxylin-eosin. a and d, x 17; b, c, e and f, x 170.
cells from different transgenic individuals, the Eli/ret pre-B-
lymphoma cell line (H-2b/d), Elt/ret primary pre-B lymphoma
(H-2b) and the MEL-ret melanoma cell line (H-2b), were
susceptible to the anti-tumour immunity. This suggested that
the induced immunity was directed against the ret-linked
antigen or the ret protein itself, which should be the only
potential candidate immunogenic element shared by the three
tumour cells as all other genetically determined antigens (H-2
and minor) of these tumours of B6 x Balb/c origin should
not be antigenic for the host F1 mice of B6 and Balb/c
strains. In agreement with this conclusion, the induced
immunity was not directed to Eplmyc pre-B lymphoma (H-
2b), which differs only at the transgenic oncogene from Eg/ret
primary pre-B lymphoma (H-2b), except for some back-
ground genes (B6 for Eft/myc and B6 x Balb/c for Eln/ret)
whose products should not be antigenic in F, mice according
to the accepted transplantation immunology rule.
The ret-linked anti-tumour immunity was induced by prim-
ing with alloantigen (H-2k/d) bearing ret-transgenic cells
(retLl-6 or retL6-6). However, the induced immunity was not
restricted by the H-2 of the cells for priming, protecting
against the challenge of both H-2bId and H-2b ret-transgenic
tumours. This finding corresponded to our previous result
that priming for the secondary CTL responses to non-H-2
cellular antigens in vivo (Mizoguchi et al., 1988) and in vitro
(Ando et al., 1988) is not restricted by the H-2 of the
immunising cells for priming, suggesting effective processing
of the tumour antigen by host cells for priming.SrImmunotherapy inEli/rettransgenk mice
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Our conclusion that the induced immunity was ret-specific
may not be surprising by itself, because the transgenic ret of
human origin as a model of homologous ret with extensive
mutation is expected to produce ret protein with xenogenic
epitopes that must be immunogenic to conventional mice.
Actually, we succeeded in demonstrating T-cell proliferation
response to recombinant ret protein that was injected with
Freund's adjuvant into BCF, mice (Dai et al., 1994). How-
ever, it was rather suprising that the immunity induced with
either ret-transgenic tumour cells (the present study) or
recombinant ret protein (Dai et al., 1994) was active in
tumour rejection (in both studies) and tumour cell killing (in
this study only), probably including helper type (in the other
study) and cytotoxic (in this study) anti-tumour T-cell
immunity.
Human proto-ret has 83% sequence homology to mouse
proto-ret (Iwamoto et al., 1993). The present results suggest
that such an oncogene product with extensive molecular
modification from the native one still works as antigen for
anti-tumour immunity. The ret protein was localised on cell
membranes (Taniguchi et al., 1992), and was not therefore
expected to work as a strong tumour rejection antigen. The
successful induction of tumour rejection immunity to this
antigen supports the view that oncogene products with
molecular modifications can induce tumour rejection
immunity, no matter what the change in the molecular struc-
ture or the cellular location of the oncogene products. How-
ever, the level of the immunity induced in the present study
was not very strong, even when the molecular variation of
the oncogene product (human vs mouse) as antigen was
extensive and a potentially powerful method of immunisation
was used. This may suggest the limitation of the immunity
specific to non-nuclear oncogene products.
Even though all the results suggest that the anti-tumour
immunity was induced by the transgenic human ret protein
bearing xenogenic epitopes or by another transgenic ret-
linked antigen, we do not know what peptide sequences of
the ret protein or ret-linked antigen are the target epitopes of
the tumour-rejecting lymphocytes. Use of transfectants of
Elt/myc pre-B lymphoma with different segments of ret
cDNA might be effective for further characterisation of the
ret or ret-linked immunogenic peptide(s) for the anti-tumour
immunity. Studies are therefore in progress to establish a
hypoxanthine-guanine-phosphoribosyl transferase (HGPRT)-
defective mutant of the EfL/myc pre-B lymphoma for selec-
tion of such transfectants and to prepare a number of
suitable gene constructs for transfection.
The epitopes that should be recognised by tumour-specific
T cells in TGM where the tumour arose might, however, be
different from those seen by the T cells in the conventional
mice transplanted with the tumour. This is because
immunological tolerance would be established against the
xenogenic epitopes on human ret protein in the T lym-
phocytes of the former but not the latter mice. For this
reason, the transgenic human ret protein might behave like a
self antigen, providing a model in which the immunology of
the self ret protein can be studied. Why, then, did tumour-
rejecting immunity develop in TGM as a result of injecting
immunising tumour cells in our study? It might be that
tolerance was incomplete. It should be remembered that, in 2
of 11 TGM in.the immunised group, no tumours developed
during the whole period examined when all TGM in the
unimmunised control group died of tumours. There might
exist a variation in the level of tolerance among individual
TGM, as was previously reported among different lines of
SV40 large T antigen TGM (Faas et al., 1987). Alternatively,
some mutation might appear in the ret oncogene during the
development of a tumour, creating a new epitope to which
TGM are not tolerant. Germline mutations of the ret proto-
oncogene have been reported in human multiple endocrine
neoplasia type IIA (Mulligan et al., 1993). It could be that
immunisation with retL6-6 potentially bearing a type of
mutation was fully protective against the tumour in which
the same type of mutation occurred, but was only partially
suppressive against the tumours bearing different types of
mutations. Presently, we do not have any evidence for or
against either of these alternative views.
Finally some points should be considered regarding the
new method of tumour modification used in this study. We
introduced H-2 alloantigen into the transgenic tumour by
breeding the TGM with an allogenec strain. This trial was an
extension of our previous experiments in which we induced
tumour rejection immunity against a chemically induced
tumour by using tumour cells transfected with an allogeneic
H-2K gene (Isobe et al., 1989). The effectiveness of introduc-
tion of the allogeneic gene in inducing tumour rejection
immunity has also been reported in a human system (Plautz
et al., 1993). Our present results further confirm the
effectiveness of this method of tumour modification, and
justify the trial of immunotherapy by introducing the MHC
gene into local tumours (Nabel et al., 1992). However, it still
remains unanswered whether or not these methods are
superior to others.
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